GLP Agonist
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrate weight reductions exceeding 17% at 24 weeks, positioning it as one of the most potent anti-obesity peptides under investigation. The glucagon receptor component augments energy expenditure and hepatic fat clearance beyond what dual agonists achieve, making it a compelling tool for metabolic disease research.
Mechanism of Action
Triple receptor co-agonism integrates incretin signaling (GIP/GLP-1) with glucagon-mediated thermogenesis, producing compounded effects on energy intake, expenditure, and substrate metabolism.
Research Applications
- → Severe obesity pharmacotherapy models
- → Hepatic lipid metabolism studies
- → Energy expenditure and thermogenesis research
- → Comparative incretin agonist trials
Analytical Validation
HPLC purity ≥ 98%; endotoxin < 1 EU/mg (LAL); lyophilized, nitrogen-blanketed vials; sequence confirmed by MS/MS.
For research use only